Sponsors (39)
The bill funds/mandates a study to produce disaggregated evidence that could improve protections for women (especially women of color) from harmful hair-straightening chemicals, but doing so may delay immediate action, leave uncertainties if data are incomplete, and could lead to higher consumer costs if new testing requirements follow.
Women—especially women of color—will gain clearer, disaggregated evidence about links between chemical hair straighteners and uterine cancer, which can support prevention, informed choices, and targeted public-health outreach.
Consumers (particularly users of hair-straightening products) may see stronger FDA safety testing and regulation of these products if the study prompts action, reducing exposure to harmful chemicals over time.
Federal policymakers and state public-health agencies will receive timely, disaggregated data (within two years) to better target regulatory and prevention efforts.
Women who use chemical hair-straightening products—particularly women of color—may remain exposed to potential carcinogens during the study period if policymakers delay immediate regulatory action until the report is complete.
Consumers and salon clients could face higher prices for hair products and services if any resulting FDA testing or compliance requirements lead manufacturers and businesses to pass costs onto customers.
Affected communities—especially women of color—may still face uncertainty if the study is constrained by data gaps or industry non-cooperation, limiting the usefulness of its findings for protection and policy.
Based on analysis of 2 sections of legislative text.
Directs HHS, with FDA and NIH, to study links between chemical hair straighteners and uterine cancer, focusing on racial disparities and product characteristics, and report in two years.
Introduced July 15, 2025 by Yvette Diane Clarke · Last progress July 15, 2025
Requires the Department of Health and Human Services, working with the FDA and NIH, to carry out a study on whether chemical hair straighteners are linked to uterine cancer, with special focus on higher rates among women of color. The law sets short deadlines: a study plan to two congressional committees within 45 days, the study must begin within 180 days, and a final report is due within two years of enactment.